U. Colorado Cancer Center Trial Shows Tucatinib Progressing in Pivotal...

Twenty-seven percent of 50 heavily pretreated patients with stage IV HER2+ breast cancer saw clinical benefit from the drug, with at least “stable disease” at 24 or more weeks after the start of...(PRWeb January 11, 2017)Read the full story at http://www.prweb.com/releases/2017/01/prweb13972581.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news